Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069935 | 0.81 | TSHR (0.58) | MAOBTSHRCA1CA2 | |
| SCHEMBL5598625 | 0.80 | RAB9A (0.40) | TP53TSHRALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6079570 | 0.79 | ALDH1A1 (0.53) | MAOBTP53TSHRALDH1A1CA1 | |
| SCHEMBL854566 | 0.78 | MAOB (0.48) | MAOBTP53TSHRALDH1A1CA1 | |
| SCHEMBL16020622 | 0.78 | ALDH1A1 (0.43) | TP53TSHRALDH1A1SMN1; SMN2KCNH2 | |
| Phenylacetaldehyde SCHEMBL2322701 | 0.77 | MAOB (0.46) | MAOBTP53TSHRALDH1A1CA1 | |
| SCHEMBL20572728 | 0.76 | MAOB (0.41) | MAOBTSHRALDH1A1CA1CA2 | |
| Allylbenzene SCHEMBL253102 | 0.75 | ALDH1A1 (0.48) | MAOBTP53TSHRALDH1A1RAB9A | |
| SCHEMBL185486 | 0.75 | MAOB (0.55) | MAOBTP53TSHRALDH1A1CA1 | |
| SCHEMBL13724166 | 0.75 | MAOB (0.40) | MAOBTSHRALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | claimed |
| EP-3983408-A1 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | 3M Innovative Properties Company (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020250089-A1 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-12-17 | — | — | WO | disclosed |
| US-8765807-B2 | Esters of capsaicin for treating pain | TRINITY LABORATORIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110218180-A1 | Esters of Capsaicin for Treating Pain | Trinity Laboratiories, Inc. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2155689-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008145681-A2 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-5580410-A | Pre-conditioning a substrate for accelerated dispersed dye sublimation printing | DELTA TECHNOLOGY, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996018509-A1 | PRE-CONDITIONING A SUBSTRATE FOR ACCELERATED DISPERSED DYE SUBLIMATION | DELTA TECHNOLOGY, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218180-A1 | Esters of Capsaicin for Treating Pain | FAAH, APEH, FFAR1 | MAOB 366/4885TP53 4589/4885TSHR 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.